Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation
Effects of Oral Care With 3% Hydrogen Peroxide (Oroxid®) on the Lower Respiratory Tract Microbial Colonisation in Mechanically Ventilated Adult Critically Ill Patients (HyPer-MICROBE Trial); a Single-centre, Randomised, Controlled Trial
Charles University, Czech Republic
160 participants
May 1, 2024
INTERVENTIONAL
Conditions
Summary
HyPerMICROBE is a single-centre, controlled, randomised, prospective, superiority clinical trial to compare the efficacy of daily oral care with 3% hydrogen peroxide (Oroxid®) versus standard of care (0.2% chlorhexidine digluconate) on the cumulative incidence of lower respiratory tract microbial colonisation in mechanically ventilated adult critically ill patients.
Eligibility
Inclusion Criteria5
- Age ≥18 years
- In-patient of ICU and expected to stay \> 5 days
- Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation (MV) ≥ 72h
- Clinical Pulmonary Infection score (CPIS) less than 6 at the baseline
- No history and symptoms of aspiration at the baseline
Exclusion Criteria5
- ATB therapy of respiratory infection on admission
- Suspected pulmonary infection on admission and in the first 48h of mechanical ventilation
- Pregnancy
- Oral ulcers or injuries
- Patient with a history of hydrogen peroxide allergy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local "ventilator bundle "; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash.
All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local "ventilator bundle "; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06045429